Food & Drink / Compounds / Bisphenol S (BPS)

Bisphenol S (BPS) in food: ingestion safety

Moderate risk

(People-specific data is limited; this page draws from human adult context.) BPA replacement in 'BPA-free' products; similar estrogenic activity in vitro; EFSA evaluation in progress (2023).

What is bisphenol s (bps)?

The IUPAC name is 4-(4-hydroxyphenyl)sulfonylphenol.

Also known as: 4-(4-hydroxyphenyl)sulfonylphenol, 4,4'-Sulfonyldiphenol, Bisphenol S, Bis(4-hydroxyphenyl) sulfone.

IUPAC name
4-(4-hydroxyphenyl)sulfonylphenol
CAS number
80-09-1
Molecular formula
C12H10O4S
Molecular weight
250.27 g/mol
SMILES
C1=CC(=CC=C1O)S(=O)(=O)C2=CC=C(C=C2)O
PubChem CID
6626

Risk for people

Moderate risk

BPA replacement in 'BPA-free' products; similar estrogenic activity in vitro; EFSA evaluation in progress (2023).

Regulatory consensus

11 regulatory and scientific bodies have classified Bisphenol S (BPS). The classifications differ — that's the data.

AgencyYearClassificationNotes
EU2023Evaluation in progressEFSA evaluation
EPA CTX / GenetoxGenotoxicity: negative (Ames: negative, 0 positive / 9 negative reports)
EPA CTX / GenetoxGenotoxicity: negative (Ames: negative, 0 positive / 9 negative reports)
EPA CTX / Skin-EyeSkin Sensitization: SkinSens1 (score: high)
EPA CTX / Skin-EyeEye Irritation: Category 6.4A (Category 2A) (score: high)
EPA CTX / Skin-EyeSkin Irritation: Category 6.3B (Category 3) (score: moderate)
EPA CTX / Skin-Eyeskin corrosion: in vitro / ex vivo: Studies Indicate No Significant Irritation (score: low)
EPA CTX / Skin-Eyeskin sensitisation: in vivo (non-LLNA): Not likely to be sensitizing (score: low)
EPA CTX / Skin-Eyeskin irritation: in vivo: Studies Indicate No Significant Irritation (score: low)
EPA CTX / Skin-Eyeeye irritation: in vivo: Studies Indicate No Significant Irritation (score: low)
EPA CTX / Skin-Eyeskin sensitisation: in vivo (LLNA): Not likely to be sensitizing (score: low)

Regulators apply different standards of evidence — animal-data weighting, exposure-pattern assumptions, epidemiological power thresholds — which is why two scientific bodies can review the same data and reach different conclusions. The disagreement is the data.

Where you encounter bisphenol s (bps)

  • Consumer ProductsPlastic bottles and containers, Food packaging, Plastic toys and household items
  • Drinking WaterLeaching from plastic pipes, Migration from bottled water containers
  • Indoor EnvironmentsOff-gassing from plastic furniture, Degradation of plastic products

Safer alternatives

Lower-risk approaches that achieve a similar outcome to Bisphenol S (BPS):

  • Bio-based polymer alternatives where available
    Trade-offs: Performance limitations. End-of-life complexity.
    Relative cost: 2-5× conventional

Frequently asked questions

What products contain bisphenol s (bps)?

Bisphenol S (BPS) appears in: Plastic bottles and containers (Consumer products); Food packaging (Consumer products); Leaching from plastic pipes (Drinking water); Migration from bottled water containers (Drinking water); Off-gassing from plastic furniture (Indoor environments).

Why do regulators disagree about bisphenol s (bps)?

Bisphenol S (BPS) has been classified by 11 agencies including EU, EPA CTX / Genetox, EPA CTX / Genetox, EPA CTX / Skin-Eye, EPA CTX / Skin-Eye, with differing conclusions. Regulators apply different standards of evidence (animal data weighting, exposure-pattern assumptions, epidemiological power thresholds), which is why two scientific bodies can review the same data and reach different conclusions. See the regulatory consensus table on this page for the full picture.

See Bisphenol S (BPS) in the food app

Look up products containing bisphenol s (bps), compare to alternatives, and explore the full data record.

Open in food View raw API data

Sources (1)

  1. EFSA: Bisphenol S — Safety Assessment (in progress) (2023) — regulatory

Reference data, not professional advice. Aggregates publicly available regulatory and scientific data; not a substitute for veterinary, medical, legal, or regulatory advice. Why we built ALETHEIA →